ClinicalTrials.gg
RecruitingNCT05824975Updated Nov 25, 2024

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

A Phase 1/2 interventional study of GI-102 subcutaneous (SC) and GI-102 in Advanced Solid Tumor, Metastatic Solid Tumor and Soft Tissue Sarcoma (STS), sponsored by GI Innovation, Inc.. Recruiting at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-25.

Sponsored by GI Innovation, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started May 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
358
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 269 studies in Neoplasm Metastasis with a site in Korea, Republic of — 59 open to participants now, 108 under way, 35 of them phase 3. Neoplasm Metastasis · Korea, Republic of.

Planned enrollment
85th of 256
358 · median 200
Started
2023
with 12 others
Phase 1/2
37 of 269
19 open now
Primary completion
2025-11
later than 20 of 107 live
Registered
213th of 269
by date

Among the 269 studies in Neoplasm Metastasis with a site in Korea, Republic of, this one is the 85th largest by planned enrollment of the 256 interventional ones that give a count, is one of 13 that started in 2023, is one of 37 in phase 1/2, reaches primary completion later than 20 of the 107 other live ones, and was the 213th registered.

Neoplasm Metastasis

4,051 studies on the registry are indexed under Neoplasm Metastasis; 893 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

59 of the 269 studies in Neoplasm Metastasis with a site in Korea, Republic of are open now. Recruiting first, the newest first:

54 more — sign in →

All 59 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 693 Neoplasm Metastasis studies recruiting now, 541 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 269 studies in Neoplasm Metastasis with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.

Read the detailed description

This is a phase 1/2, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, and anti-tumor effect of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors. This study is adaptive in nature.

The study is composed of four parts:

  • Part A: Dose escalation and optimization phase of GI-102 intravenous (IV) monotherapy

    • Part A dose escalation phase
    • Part A dose optimization phase: Dose optimization cohorts in patients with 2L+, CPI-refractory metastatic melanoma
  • Part B: Dose escalation and expansion phase of GI-102 subcutaneous (SC) monotherapy
  • Part C: Indication specific cohorts of GI-102 IV in combination with conventional anti-cancer drugs or trastuzumab deruxtecan (T-DXd)
  • Part D: Indication specific cohorts of GI-102 IV in combination with pembrolizumab

GI-102 is a novel bi-specific Fc fusion protein containing the CD80 ectodomain as an N-terminal moiety and an interleukin (IL)-2 variant as a C-terminal moiety configurated via a human immunoglobulin G4 (IgG4) Fc. GI-102 has unique characteristics by having bispecificity to CD80 and IL2Rβγ. The CD80 portion is responsible for targeting tumor/immune cells while blocking CTLA-4 expressed on the Treg cells. The IL-2v of GI-102 is designed to abolish IL-2Rα affinity and therefore minimize the effect on Treg while it has very outstanding effect on NK and CD8 T cell proliferation and activity through IL-2Rbr affinity.

03

Conditions studied

  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Soft Tissue Sarcoma (STS)
  • Platinum-resistant Ovarian Cancer (PROC)
  • Hepatocellular Carcinoma (HCC)
  • Colorectal Cancer (CRC)
  • HER2 Negative Breast Cancer
  • Cutaneous Melanoma
  • Renal Cell Carcinoma (RCC)

Keywords

  • GI-102
  • CD80-IgG4 Fc-IL2 variant
  • Immunotherapy
  • IL-2
  • Interleukin-2
  • bispecific protein
  • immunocytokine
  • CD80
  • CTLA-4
  • Pembrolizumab
  • T-DXd
  • Trastuzumab deruxtecan
  • Doxorubicin
  • Paclitaxel
  • Bevacizumab
  • Eribulin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Males and females aged ≥ 18 years (or ≥ 19 years according to local regulatory guidelines) at the time of screening.
  • Has adequate organ and marrow function as defined in protocol.
  • as per v1.1.
  • performance status 0-1.
  • Adverse events related to any prior chemotherapy, radiotherapy, immunotherapy, other prior systemic anti-cancer therapy, or surgery must have resolved to Grade ≤1, except alopecia and Grade 2 peripheral neuropathy.
  • infected patients must be on anti-retroviral therapy (ART) and have a well-controlled HIV infection/disease as defined in protocol.

Key Exclusion Criteria:

  • Has known active and/or carcinomatous meningitis.
  • An active second .
  • Has active or a known history of or known active virus infection.
  • Has active tuberculosis or has a known history of active tuberculosis.
  • Active or uncontrolled infections, or severe infection within 4 weeks before study treatment administration.
  • History of chronic liver disease or evidence of hepatic cirrhosis, except patients with liver .
  • Has an active disease that has required systemic treatment in past 2 years.
  • Previous immunotherapies related to mode of action of GI-102.
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy or any other form of medications within 2 weeks prior to Cycle 1 Day 1.
  • Administration of prior systemic anti-cancer therapy including agents within 4 weeks prior to treatment.
  • Radiotherapy within the last 2 weeks before start of study treatment administration, with exception of limited field palliative radiotherapy.
  • Administration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1.
  • Known to any of the components of the drug products and/or of GI-102.

Other protocol defined inclusion exclusion criteria may apply

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
358 participants (estimated)

Study arms

  • Experimental
    GI-102

    Dose escalation: GI-102 intravenous (IV), multiple ascending doses Dose optimization: GI-102 intravenous (IV), sRP2D Dose optimization: GI-102 intravenous (IV), sRP2D-1 (or sRP2D+1)

    Drug: GI-102

  • Experimental
    GI-102 subcutaneous (SC)

    Dose escalation: GI-102 subcutaneous (SC), multiple ascending doses Dose expansion: GI-102 subcutaneous (SC), sRP2D

    Drug: GI-102 subcutaneous (SC)

  • Experimental
    GI-102 + doxorubicin

    Drug: doxorubicin · Drug: GI-102

  • Experimental
    GI-102 + paclitaxel + bevacizumab

    Drug: paclitaxel · Drug: bevacizumab · Drug: GI-102

  • Experimental
    GI-102 + eribulin

    Drug: eribulin · Drug: GI-102

  • Experimental
    GI-102 + trastuzumab deruxtecan (T-DXd)

    Drug: trastuzumab deruxtecan (T-DXd) · Drug: GI-102

  • Experimental
    GI-102 + pembrolizumab

    Drug: pembrolizumab · Drug: GI-102

Interventions

  • 0.12 mg/kg, 0.24 mg/kg or Recommended phase 2 dose of GI-102 will be administered via SC injection Q3W up to 2 years (approximately 35 years).

  • DrugGI-102

    Dose level will be escalated from 0.06 mg/kg to 0.45 mg/kg and Recommended phase 2 dose (or RP2D-1, RP2D+1) of GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).

  • Doxorubicin will be administered intravenously at a dose of 75 mg/m2 on Day 3 every 3-week (21-day) cycle for up to 6 cycles.

  • Paclitaxel will be administered intravenously over 1 hour at a dose of 80 mg/m2 each time weekly as a diluted solution according to the prescribing information.

  • Bevacizumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks.

  • Eribulin will be administered intravenously at a dose of over 1.4 mg/m2 over 2 to 5 minutes on Days 3 and 10 every 3-week (21-day) cycle.

  • T-DXd will be administered initially as a 5.4 mg/kg (or 6.4 mg/kg only for gastric cancer) IV over 30 - 90 minutes every 3 weeks.

    Also known as: ENHERTU®

  • pembrolizumab will be administered at a dose of 200 mg as IV infusion Q3W.

    Also known as: KEYTRUDA®

  • DrugGI-102

    Recommended phase 2 dose (or RP2D-1, RP2D-2) of GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).

06

What researchers measure

Primary outcomes

  1. Incidence and nature of Dose-Limiting Toxicity (DLTs) (dose escalation phase of Part A and B)

    A DLT is defined as a clinically significant AE (classified according to the NCI CTCAE version 5) or significant laboratory abnormality that occur during the DLT assessment periods, during dose escalation and dose expansion, and is considered by the Investigator to be related to GI-102.

    Time frame: Study Day 1, assessed up to DLT period (3 weeks after treatment)

  2. Incidence, nature, and severity of adverse events (AEs) and immune-related AEs (irAEs) (dose escalation phase of Part A and B)

    An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. All AE events will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: Study Day 1, assessed up to approximately 24 months

  3. Objective Response Rate (ORR) (dose optimization phase of Part A, dose expansion phase of Part B, Part C and D)

    ORR is defined as the percentage of participants with investigator-assessed objective response of complete response (CR) or partial response (PR). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions).

    Time frame: Study Day 1, assessed up to approximately 24 months

Secondary outcomes

  1. Objective Response Rate (ORR) (dose escalation phase of Part A and B)

    ORR is defined as the percentage of participants with investigator-assessed objective response of complete response (CR) or partial response (PR). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions).

    Time frame: Study Day 1, assessed up to approximately 24 months

  2. Incidence and nature of Dose-Limiting Toxicity (DLTs) (dose optimization phase of Part A, dose expansion phase of Part B, Part C and D)

    A DLT is defined as a clinically significant AE (classified according to the NCI CTCAE version 5) or significant laboratory abnormality that occur during the DLT assessment periods, during dose escalation and dose expansion, and is considered by the Investigator to be related to GI-102.

    Time frame: Study Day 1, assessed up to DLT period (3 weeks after treatment)

  3. Incidence, nature, and severity of adverse events (AEs) and immune-related AEs (irAEs) (dose optimization phase of Part A, dose expansion phase of Part B, Part C and D)

    An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. All AE events will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: Study Day 1, assessed up to approximately 24 months

  4. Disease Control Rate (DCR)

    DCR is defined as the percentage of patients who have achieved CR, PR and stable disease (SD), per RECIST v1.1 guideline as determined by the investigators.

    Time frame: Study Day 1, assessed up to approximately 24 months

  5. Duration of objective response (DoR)

    DCR is defined as the time from the first occurrence of a documented objective response to the time of the first document disease progression or death from any cause, whichever occurs first, per RECIST v1.1 as determined by the investigator.

    Time frame: Study Day 1, assessed up to approximately 24 months

  6. Progression-free survival (PFS)

    PFS is defined as the time from the first study treatment (Day 1) to the first occurrence of progression or death from any cause, whichever occurs first, per RECIST v1.1 guideline as determined by the investigator

    Time frame: 6-month, 12-month, and 18-month

  7. Overall survival (OS)

    OS is defined as the time from the first study treatment to death from any cause

    Time frame: 12-month and 18-month

  8. Peak plasma concentration (Cmax) of GI-102

    Based on the concentration vs time profile by dose level

    Time frame: Study Day 1, assessed up to approximately 24 months

  9. Half-life of GI-102 (T1/2)

    Based on the concentration vs time profile by dose level

    Time frame: Study Day 1, assessed up to approximately 24 months

  10. Area under the plasma concentration versus time curve (AUC) of GI-102

    Based on the concentration vs time profile by dose level

    Time frame: Study Day 1, assessed up to approximately 24 months

  11. Clearance of GI-102

    Based on the concentration vs time profile by dose level

    Time frame: Study Day 1, assessed up to approximately 24 months

  12. Volume of distribution (Vd) of GI-102 after administration

    Based on the concentration vs time profile by dose level

    Time frame: Study Day 1, assessed up to approximately 24 months

Other outcomes

  1. Incidence of anti-GI-102 antibody (ADA) and neutralizing antibody (Nab)

    Serum will be assessed for the presence of ADA and Nab based on the appropriate assay.

    Time frame: Study Day 1, assessed up to approximately 24 months

  2. Immunophenotyping of peripheral blood CD4+ T cells

    CD4+ T cells in peripheral blood will be assessed by flow cytometry at various time points

    Time frame: Study Day 1, assessed up to approximately 24 months

  3. Immunophenotyping of peripheral blood CD8+ T cells

    CD8+ T cells in peripheral blood will be assessed by flow cytometry at various time points

    Time frame: Study Day 1, assessed up to approximately 24 months

  4. Immunophenotyping of peripheral blood Treg cells

    Treg cells in peripheral blood will be assessed by flow cytometry at various time points

    Time frame: Study Day 1, assessed up to approximately 24 months

07

Study locations

11 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Nov 2025, 29 months after the start.

Of 129 industry-sponsored phase 1/2 interventional studies under Neoplasm Metastasis, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 89. This study's planned 29 months is below that.

Counting every sponsor, half of 215 studies reached it within 62 months; a quarter within 41 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2023
First posted
Apr 24, 2023
StartActual
May 30, 2023
Primary completionEst.
Nov 12, 2025
CompletionEst.
Apr 24, 2027
Last update
Nov 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05824975
Lead sponsor
GI Innovation, Inc.
Responsible party
Sponsor
First posted
Apr 24, 2023
Start date
May 30, 2023
Primary completion
Nov 12, 2025 (estimated)
Completion
Apr 24, 2027 (estimated)
Last update
Nov 25, 2024

Study contacts

Jay Kim
Contact
Clinical-102@gi-innovation.com
+82-2-404-2003
Woosun Lee
Contact
Clinical-102@gi-innovation.com
+82-2-404-2003
Nari Yun, PhD
study director · GI Innovation, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102

Start the discussion